[New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].
Lennerstrand
Johan
J
johan.lennerstrand@medsci.uu.se
Bondeson
Kåre
K
Bergqvist
Anders
A
Blomberg
Jonas
J
Oberg
Bo
B
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000069616:Simeprevir; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome; D017361:Viral Nonstructural Proteins / Q000737:chemistry / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase
D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D009842:Oligopeptides; D011392:Proline; D011480:Protease Inhibitors; D000069616:Simeprevir; D013449:Sulfonamides; D017361:Viral Nonstructural Proteins; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase